Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded, unstable proteins caused by genetic mutations. This technology represents a novel, next-generation approach to the management of human genetic diseases and offers the potential to improve treatment options for many patients. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. The company believes pharmacological chaperone technology has broad applicability and expects to expand the portfolio to include other diseases of neurodegeneration, metabolic diseases, and oncology. Founded in 2002, Amicus has assembled an outstanding leadership team that includes scientific, medical, regulatory, and business professionals with successful track records of developing and bringing to market drugs for genetic diseases. Amicus continues to develop its pharmacological chaperone technology and has built a significant intellectual property portfolio along with its robust clinical and preclinical pipeline. Amicus has a fast-paced, high-energy, entrepreneurial team environment where employees are encouraged to be innovative and resourceful. Amicus seeks high-caliber, talented individuals with a passion to succeed.
Company Growth (employees)
Type
Public
HQ
Cranbury Township, US
Founded
2002
Size (employees)
263 (est)+43%
Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury Township, US

Key People at Amicus Therapeutics

William D. Chip Baird

William D. Chip Baird

Chief Financial Officer
Bradley L Campbe

Bradley L Campbe

Chief Operating Officer
Jeffrey P Castelli

Jeffrey P Castelli

Vice President
Enrique Diloné

Enrique Diloné

Vice President
Jay A Barth

Jay A Barth

Chief Medical Officer
Hung Do

Hung Do

Senior Vice President

Amicus Therapeutics Office Locations

Amicus Therapeutics has offices in Cranbury Township, Denham, Munich, Puteaux and in 1 other locations
Cranbury Township, US (HQ)
1 Cedar Brook Drive
Puteaux, FR
Tour Défense 2000

Amicus Therapeutics Metrics

Amicus Therapeutics Financial Metrics

Revenue (2016)

$5 m

Gross profit

$4.1 m

Gross profit margin (2016), %

83%

Net income (2016)

($200 m)

Market capitalization (21-Mar-2017)

$1.4 b

Closing share price (21-Mar-2017)

$7.3

Cash (31-Dec-2016)

$187 m
Amicus Therapeutics's current market capitalization is $1.4 b.
Amicus Therapeutics's revenue was reported to be $5 m in FY, 2016
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$122.2 m$1.2 m$5 m

Revenue growth, %

(99%)(100%)

Cost of goods sold

$833 k

Gross profit

$4.1 m

Gross profit Margin, %

83%

Operating expense total

$527.8 m$69.9 m$130.4 m$186 m

EBIT

($405.6 m)($68.7 m)($130.4 m)($181.9 m)

EBIT margin, %

(332%)(5613%)(3669%)

Interest expense

$46 k$1.5 m$1.6 m$5.4 m

Interest income

$174 k$223 k$929 k$1.6 m

Income tax expense

$3.5 m$1.1 m$1.1 m$3.7 m

Net Income

($378.5 m)($68.9 m)($132.1 m)($200 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$43.6 m$24.1 m$69.5 m$187 m

Accounts Receivable

$1.3 m

Inventories

$5.5 m$2.9 m$2.6 m$3.4 m

Current Assets

$88.3 m$154.6 m$216.6 m$340.1 m

Goodwill

$11.6 m$11.6 m$197.8 m$197.8 m

Total Assets

$127.6 m$210 m$908.4 m$1 b

Accounts Payable

$10.2 m$16.3 m$32.2 m

Current Liabilities

$10.5 m$20.2 m$73.6 m$111 m

Additional Paid-in Capital

$423.6 m$568.7 m$917.5 m$1.1 b

Retained Earnings

($447.4 m)($579.6 m)($779.6 m)

Total Equity

$45.8 m$122.2 m$347.8 m$360.2 m

Financial Leverage

2.8 x1.7 x2.6 x2.9 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($59.6 m)($68.9 m)($132.1 m)($200 m)

Depreciation and Amortization

$1.7 m$1.5 m$1.8 m$3.2 m

Accounts Receivable

($1.4 m)

Inventories

($3.2 m)$2.3 m$308 k($3.7 m)

Accounts Payable

$6.2 m$15.5 m$7.1 m

Cash From Operating Activities

($45.8 m)($51.7 m)($100.1 m)($150.5 m)

Purchases of PP&E

($695 k)($238 k)($4.8 m)($6 m)

Cash From Investing Activities

($145.3 m)($4.5 m)

Interest Paid

$30 k$1.2 m$605 k$3 m

Amicus Therapeutics Market Value History

Amicus Therapeutics Online Presence

Amicus Therapeutics Company Life

You may also be interested in